The data support azetukalner as a best-in-class therapy for treatment-resistant epilepsy, with strong efficacy, long-term seizure freedom, and patient-friendly dosing. With NDA submission expected in Q3 2026, XENE is a compelling near-term regulatory catalyst play. Traders should monitor for FDA feedback and potential partnership interest.
Price Chart
Executive Summary
Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 and long-term open-label data for azetukalner in focal onset seizures at the AAN 2026 meeting, showing statistically significant and durable seizure reduction, with nearly 40% of long-term patients achieving at least 12 months of seizure freedom. The company plans to submit an NDA to the FDA in Q3 2026.
Key Facts
- Azetukalner 25 mg achieved a 53.2% reduction in monthly seizure frequency vs. 10.4% for placebo (p<0.0001) in the Phase 3 X-TOLE2 trial.
- Long-term data from the X-TOLE OLE study show 38.2% of patients treated for ≥48 months achieved at least 12 months of seizure freedom.
- Azetukalner demonstrated consistent safety with low rates of serious adverse events (5.6% in 25 mg group vs. 2.4% placebo).
- Xenon plans to submit an NDA for azetukalner in epilepsy to the FDA in Q3 2026.
Financial Impact
High commercial potential in a $5B market; azetukalner could capture significant share given best-in-class efficacy and no-titration advantage.
Risk Factors
- Regulatory delay or rejection of NDA submission
- Competition from established ASMs and emerging therapies
- Potential safety signals in larger patient populations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276673 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 2, 2026 13w ago | Press Release | $60.96 $64.19 | ▲ +5.30% | ▲ +5.71% | $38.02 (−37.63%) |
Jun 5, 2026 17w ago | 144 | $51.21 $60.54 | ▲ +18.22% | ▲ +16.59% | $38.02 (−25.76%) |
Jun 3, 2026 17w ago | 8-K | $52.99 $60.96 | ▲ +15.04% | ▲ +16.41% | $38.02 (−28.25%) |
May 7, 2026 21w ago | Press Release | $56.44 $51.73 | ▼ −8.35% | ▼ −8.37% | $38.02 (−32.64%) |
Apr 22, 2026 23w ago | DEFA14A | $55.41 $54.68 | ▼ −1.32% | ▼ −5.95% | $38.02 (−31.38%) |
Apr 19, 2026 23w ago | Press Release | $57.09 $53.71 | ▼ −5.92% | ▼ −10.12% | $38.02 (−33.40%) |
Apr 15, 2026 24w ago | Press Release | $58.88 $55.00 | ▲ +6.59% | ▲ +12.63% | $38.02 (+35.43%) |
Apr 13, 2026 24w ago | 8-K | $59.35 $55.78 | ▼ −6.02% | ▼ −12.31% | $38.02 (−35.94%) |
Apr 7, 2026 25w ago | Press Release | $57.65 $57.40 | ▲ +0.43% | ▲ +10.21% | $38.02 (+34.05%) |
Mar 13, 2026 29w ago | Insider Cluster | $55.23 $58.60 | ▼ −6.10% | ▼ −2.51% | $38.02 (+31.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access